A vancomycin trough should be drawn within 30 minutes before the next scheduled dose, and only after the drug has reached steady state in the bloodstream, which generally means waiting until at least the fourth dose has been given. That sounds simple enough, but hospital data consistently show that the majority of trough samples are mistimed, and the consequences of getting it wrong are not trivial. The reasons timing matters so much, and the situations that make proper timing harder to achieve, are worth understanding in detail.
The 30-Minute Window
The standard recommendation is to draw the blood sample no more than 30 minutes before the next vancomycin dose is due. At that point, the drug concentration in the blood has fallen to its lowest point in the dosing cycle, which is what a “trough” level is supposed to capture. If the sample is collected an hour or more before the next dose, the drug is still being cleared from the body and the concentration is higher than the true trough. If the sample is drawn after the next dose has already started infusing, the new drug entering the bloodstream contaminates the reading entirely.
One study at a large academic medical center found that before implementing trough-timing guidelines, only about 37% of vancomycin troughs were drawn within 30 minutes of the next dose. After guidelines were introduced, that rate jumped to 78%.
1PubMed. Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring Even with active guideline enforcement, roughly one in five draws remained mistimed. Across multiple hospitals, the problem is often worse: a retrospective study of vancomycin trough samples found that about 80% were incorrectly timed, with fewer than one in five collected within the optimal window.2PubMed Central. Therapeutic drug monitoring of vancomycin: A retrospective cross-sectional study of blood draw timing and clinical outcomes
What Happens When the Draw Is Too Early
Drawing the trough too early is the most common timing error, and the clinical downstream effects are well documented. At one academic center, about 41% of vancomycin levels were drawn too early. Those mistimed samples showed average concentrations significantly higher than correctly timed ones, roughly 22 mg/L versus about 16 mg/L.3American Journal of Clinical Pathology. What Proportion of Vancomycin Trough Levels Are Drawn Too Early? Frequency and Impact on Clinical Actions That gap matters because clinicians act on the number they see. When the trough looks artificially high, the prescribing team is more likely to lower the dose, hold the next dose, or stop the drug altogether. In that same study, clinicians decreased, discontinued, or held vancomycin about 26% of the time after early draws, compared with 21% after correctly timed draws. They were also much more likely to order a repeat level, adding cost and another needle stick.
The practical result is underdosing. A patient whose true trough is actually in the therapeutic range gets a falsely elevated reading, and their dose gets cut. For serious infections like MRSA bloodstream infections, underdosing can mean treatment failure. The irony is that a lab test intended to protect the patient ends up putting them at risk when it is performed at the wrong time.
Timing Errors and Patient Outcomes
Beyond the immediate dosing decisions, incorrect trough timing has been linked to worse clinical outcomes. In a retrospective study comparing correctly and incorrectly timed vancomycin samples, clinical cure rates were 75% among patients whose samples were properly timed versus about 58% among those with mistimed draws.2PubMed Central. Therapeutic drug monitoring of vancomycin: A retrospective cross-sectional study of blood draw timing and clinical outcomes For specific infection sites like lung and skin infections, the gap was even wider. Improper timing was also associated with higher in-hospital mortality (about 30%) and a higher rate of acute kidney injury (roughly 16%). These are observational associations, so it is possible that sicker patients just happened to have more chaotic care schedules, leading to more mistimed draws. But the signal is strong enough to take seriously.
Waiting for Steady State
Even if the 30-minute window is hit perfectly, the trough is unreliable if the drug has not yet reached steady state. Steady state is the point at which the amount of drug entering the body with each dose roughly equals the amount being cleared between doses, so concentrations settle into a predictable cycle. For most adults with normal kidney function on a standard every-8-hour or every-12-hour vancomycin regimen, this takes about three to five doses, typically meaning the first useful trough can be drawn before the fourth dose.
Drawing a trough before steady state consistently underestimates where the drug concentration will eventually land. A large retrospective analysis at Mayo Clinic found that among over 5,300 vancomycin courses, about half of patients ended up with a steady-state trough outside the target range, suggesting that even with monitoring, it is hard to predict where a given patient will settle.4PubMed Central. Determining steady-state trough range in vancomycin drug dosing using machine learning Drawing the level too soon just compounds that unpredictability.
When Kidneys Do Not Clear the Drug Normally
Patients with impaired kidney function are a special case because vancomycin is almost entirely cleared through the kidneys. When kidney function is reduced, the drug lingers longer, and steady state takes longer to reach. This makes the timing of the first trough particularly tricky.
A study of patients with reduced kidney function receiving once-daily vancomycin found that drawing the trough on day 3 versus day 4 made a meaningful difference. On day 3, trough concentrations were on average about 35% higher at the follow-up draw, meaning the day-3 value underestimated where levels were heading. By day 4, the increase was smaller, around 17%. Drawing on day 3 was identified as an independent risk factor for underestimating the eventual steady-state level in these patients.5PubMed. Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin For patients with compromised kidneys on once-daily dosing, waiting until at least day 4 for the initial trough gives a more honest reading.
For patients on dialysis, the picture becomes more complicated still. Vancomycin is partially removed by dialysis, and the extent depends on the type of dialysis, the membrane used, and the duration of each session. In hemodialysis patients, vancomycin levels are typically drawn before a dialysis session to get a pre-dialysis trough, then sometimes again after the session to see how much was removed.6PubMed Central. Clinical review: use of vancomycin in haemodialysis patients For patients on continuous renal replacement therapy in the ICU, trough monitoring follows the same before-next-dose principle, but the dialysis rate itself becomes a variable that affects how quickly vancomycin is cleared.7PubMed. Determinants of Vancomycin Trough Concentration in Patients Receiving Continuous Veno-Venous Hemodialysis
Why High Troughs Are Dangerous
Getting the trough right is not just about making sure the drug is effective. It is also about avoiding toxicity, particularly kidney damage. A meta-analysis examining the link between vancomycin trough levels and acute kidney injury found a clear dose-response relationship: as trough levels climbed, so did the risk of kidney injury, and the curve steepened at higher concentrations rather than rising in a straight line.8Journal of Antimicrobial Chemotherapy. Relationship of vancomycin trough levels with acute kidney injury risk: an exposure–toxicity meta-analysis In critically ill elderly adults, each 1 mg/L increase in trough concentration was associated with roughly a 2.5% increase in the odds of vancomycin-associated acute kidney injury. The risk became statistically significant once troughs exceeded about 20 mg/L for kidney injury and about 19 mg/L for 30-day mortality.9PubMed Central. Association between trough serum vancomycin concentration and vancomycin-associated acute kidney injury and 30-day mortality in critically ill elderly adults
Separate research has identified troughs at or above 14 mg/L, therapy lasting seven or more days, and pre-existing kidney issues as independent predictors of vancomycin-related nephrotoxicity.10PubMed. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity The clinical tension is real: for serious MRSA infections, guidelines have historically recommended troughs of 15 to 20 mg/L to ensure adequate drug exposure,11PubMed Central. Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort but that range sits right at the threshold where kidney injury risk starts to climb. That tension is one of the driving forces behind the shift toward a different way of monitoring vancomycin altogether.
The Shift From Trough Monitoring to AUC-Guided Dosing
The most significant change in vancomycin monitoring in recent years has been the move away from relying solely on trough levels. Revised consensus guidelines now recommend targeting the area under the concentration-time curve, or AUC, for patients with suspected or confirmed serious MRSA infections. The recommended AUC target is 400 to 600 mg·h/L per day.12Clinical Infectious Diseases. Vancomycin Area Under the Curve–Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections
The AUC captures total drug exposure over a dosing interval rather than just the lowest point. Two patients can have the same trough but very different AUCs depending on how the drug is distributed and cleared. A trough of 15 mg/L in one patient might reflect an AUC of 450, well within target, while another patient with the same trough could have an AUC of 650, putting them in a range associated with kidney toxicity. The trough alone cannot distinguish between the two.
In practice, AUC-guided dosing is typically calculated using Bayesian software that takes one or two blood sample concentrations along with patient-specific information and models the expected concentration curve. This is where timing still matters, just differently.
One-Point Versus Two-Point Sampling for AUC
When clinicians use AUC-guided monitoring, they can draw a single trough sample and let Bayesian software estimate the full curve, or they can draw two samples: a peak (typically one to two hours after the infusion ends) and a trough. Two-point sampling generally gives a more robust estimate, particularly when it comes to tolerating small errors in the trough draw time. One study found that two-point sampling remained acceptably accurate even when the trough was drawn up to 105 minutes early, while one-point sampling lost accuracy after only about 30 minutes of trough-time error.13PubMed. Quantifying the Impact of Discrepancies Between Actual and Recorded Blood Sampling Times on Bayesian Forecasting for Area Under the Concentration-Time Curve Estimation of Vancomycin
However, the peak sample introduces its own vulnerability. Peak timing is extremely sensitive: a discrepancy of even 20 minutes between the actual draw time and the time recorded in the chart can throw off the AUC estimate substantially. If the exact peak sampling time cannot be verified, clinicians may actually be better off sticking with a single trough sample rather than adding an unreliable peak.
Certain patient populations benefit more from two-point sampling. Patients with enhanced renal function (often younger, critically ill patients whose kidneys are clearing drug faster than expected), patients with severe heart failure, and patients on specific blood pressure medications showed improved AUC prediction accuracy when both a peak and a trough were used.14PubMed. Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation Meanwhile, in adult patients without kidney impairment, one hospital’s experience showed that AUC estimates using just a trough concentration performed comparably to those using both peak and trough values, with slightly better precision in some measures.15Ann Lab Med. Evaluation of Vancomycin Area Under the Concentration–Time Curve Predictive Performance Using Bayesian Modeling Software With and Without Peak Concentration The takeaway is pragmatic: two-point sampling is theoretically better but only if the timing of the peak draw is precise and reliably documented.
Vancomycin Monitoring in Patients With Obesity
Obesity changes how vancomycin distributes and clears, which has direct implications for when and how often troughs should be checked. Obese patients tend to run higher trough levels at standard doses. One study found that obese patients had significantly higher mean trough concentrations compared to non-obese patients, about 16.5 mg/L versus 12.1 mg/L, and were roughly four times more likely to have a trough above 20 mg/L.16PubMed Central. The association of elevated trough serum vancomycin concentrations with obesity
On top of that, vancomycin tends to accumulate over time in obese patients. A study looking at patients with obesity found that about 61% experienced drug accumulation within the first 10 days of therapy, with an even higher rate in ICU patients.17PubMed Central. Evaluation of Vancomycin Accumulation in Patients With Obesity This means that an initial trough that looks fine may not reflect where the level will be several days later. More frequent monitoring, especially in the first week, is warranted.
Research in this population has also highlighted a problem with using troughs alone to guide therapy. In patients with very high body weight, trough levels are a poor surrogate for AUC. Lower total daily doses can still achieve adequate AUC targets while producing trough values that would look sub-therapeutic by traditional standards. Both a peak and a trough measurement improve AUC prediction in obese patients, and emerging data support that using lower doses guided by AUC can reduce kidney injury risk.18Journal of Antimicrobial Chemotherapy. Dosing vancomycin in the super obese: less is more
Pediatric Timing Differences
Children are not small adults when it comes to vancomycin. Newborns clear the drug slowly, with a half-life of about seven hours, but clearance roughly doubles by three months of age and continues to rise. Between ages four and eight, the half-life drops to around two to three hours, meaning kids in that age range chew through vancomycin much faster than adults do. Clearance gradually approaches adult levels around age 12.19PubMed Central. Evaluation of vancomycin initial trough levels in children: A 1-year retrospective study
These pharmacokinetic differences mean that the timing of troughs in children depends heavily on age and dosing frequency. A child on every-6-hour dosing reaches steady state faster than a neonate on every-12-hour or every-24-hour dosing. The 30-minutes-before-next-dose rule still applies, but the dose before which you draw and the day on which you start monitoring should be adjusted for the child’s age-specific clearance rate. In very young neonates, the first trough is often drawn before the third or fourth dose, while in older children on frequent dosing, steady state may arrive sooner.
False Readings From Central Lines
Where you draw the blood from can matter as much as when you draw it. Samples drawn from implanted central venous catheters, such as port-a-caths, can produce spuriously high vancomycin levels. In documented cases, concentrations drawn from the port were greater than 100 mg/L while a simultaneous peripheral blood sample showed a therapeutic level of 15 mg/L.20PubMed Central. Falsely elevated vancomycin plasma concentrations sampled from central venous implantable catheters (portacaths) The cause appears to be residual vancomycin that adsorbs onto the catheter material and then leaches back into the sample when blood is withdrawn. This can happen even days after the last infusion through that line.
The clinical implication is straightforward: whenever possible, vancomycin trough samples should be drawn from a peripheral vein, not from the line used for infusion. If a peripheral draw is not feasible, clinicians should be aware that the result may be falsely elevated and should not make dose reductions based on a suspiciously high value from a central line without confirmation.
Continuous Infusion Changes the Monitoring Equation
Some institutions use continuous infusion vancomycin, where the drug runs at a steady rate rather than being given as intermittent doses. This approach eliminates the peak-and-trough cycle entirely. Instead, clinicians monitor a steady-state concentration, which can be drawn at any time once the infusion has been running long enough to reach equilibrium, typically 24 to 48 hours.21PubMed. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion The main practical advantage is that it sidesteps the timing headaches that plague trough monitoring. There is no 30-minute window to hit, no risk of drawing too early, and no concern about whether the next dose has already started. For institutions struggling with high rates of mistimed troughs, continuous infusion offers a way to get reliable drug levels without depending on precise coordination between nursing, pharmacy, and phlebotomy schedules.
Improving Trough Timing in Hospitals
Given how often troughs are mistimed, hospitals have tried various interventions to improve accuracy. Electronic health record tools that link the vancomycin level order directly to the medication administration record have shown promise. One hospital’s implementation of such a system cut the rate of missed or incorrectly timed levels from 36% to about 11%.22PubMed. Optimizing the correct timing of vancomycin level collection utilizing a vancomycin medication administration record (MAR) level order By automatically generating a timed lab order based on when the next vancomycin dose is scheduled, these systems take the guesswork out of the process for nurses and phlebotomists.
Education-only interventions have had more modest results. One initiative that focused on teaching nursing and phlebotomy staff about proper timing reduced errors from 39% to 32%, but the improvement was not statistically significant.23American Journal of Clinical Pathology. An Intervention to Improve the Timing of Vancomycin Levels The pattern across the literature is consistent: knowledge alone does not fix the problem. The bottleneck is operational. Nurses manage multiple patients with overlapping medication schedules, phlebotomists follow pre-set lab draw rounds that may not align with vancomycin dosing times, and dose timing itself can shift if an infusion is delayed. System-level solutions that embed the timing logic into the order workflow have outperformed educational campaigns.
Dosing frequency may also affect timing accuracy. In one study, patients receiving vancomycin three times daily were about five times more likely to have a correctly timed trough compared to those on twice-daily dosing.2PubMed Central. Therapeutic drug monitoring of vancomycin: A retrospective cross-sectional study of blood draw timing and clinical outcomes The likely explanation is practical: with more frequent dosing, there are more opportunities for the lab draw to coincide with a pre-dose window, and the intervals between doses are shorter, so the window is not as far from routine phlebotomy rounds.